POLYMORPHIC DEBRISOQUIN METABOLISM IN A TURKISH POPULATION

BOZKURT A., BASCI N. E., ISIMER A., SAYAL A., KAYAALP S.

CLINICAL PHARMACOLOGY & THERAPEUTICS, cilt.55, sa.4, ss.399-401, 1994 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 4
  • Basım Tarihi: 1994
  • Doi Numarası: 10.1038/clpt.1994.48
  • Dergi Adı: CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.399-401
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Debrisoquin hydroxylation polymorphism was studied in 326 unrelated healthy Turkish volunteers. Debrisoquin sulfate (10 mg) was administered to subjects, and debrisoquin and 4-hydroxydebrisoquin were determined in the 0- to 8-hour urine samples. Debrisoquin oxidation was polymorphic, with 11 subjects (3.37%; 95% confidence interval, 1.69% to 6.07%) phenotyped as poor metabolizers. The metabolic ratio between debrisoquin and 4-hydroxydebrisoquine in 8-hour urine samples ranged from 0.02 in extensive metabolizers to 263.8 in poor metabolizers. The proportion of poor metabolizers was found to be in the range observed in the other white populations studied.